ERBB2 and breast cancer: While similar multivariable analysis in the HER2+ LN- group (HR=2.28, 95%CI 1.00-5.22, p=0.052) did not emerge to statistical significance to confirm the prognostic importance of MALAT1 expression in this subgroup of patients (that had been noted on the initial univariate analysis), this effect is likely secondary to limitations of the sample size and merits investigation in a larger breast cancer patient cohort.